Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 4 | — | — | — | 5 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | 2 | 4 | — | — | — | 5 |
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
Drug common name | VOBARILIZUMAB |
INN | vobarilizumab |
Description | Vobarilizumab (INN; development code ALX0061) is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.
|
Classification | Antibody |
Drug class | antiviral (arildone derivatives); monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | 7XL0 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3833343 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 9OD8ISS64U (ChemIDplus, GSRS) |